ESC Premium Access

Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study

Congress Session

About the speaker

Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)
70 presentations
5 followers

20 more presentations in this session

Prothrombin activation fragment (F1+2) as an index of anticoagulant therapy with factor Xa inhibitor in atrial fibrillation

Speaker: Doctor E. Ueno (Kahoku, JP)

Thumbnail

Is there a difference in treatment persistence across oral anticoagulants? Results of a UK cohort study evaluating oral anticoagulation therapy in an atrial fibrillation population

Speaker: Ms G. Stynes (Uxbridge, GB)

Thumbnail

Differences in the characteristics of patients with non-valvular atrial fibrillation who are newly prescribed apixaban, rivaroxaban, dabigatran and VKA in general practice in the UK

Speaker: Ms G. Stynes (Uxbridge, GB)

Thumbnail

The HAS-BLED score for prediction of stroke and systemic embolism: insights from the PREvention oF thromboembolic events, European Registry in Atrial Fibrillation (PREFER in AF)

Speaker: Doctor M. Rohla (Bern, AT)

Thumbnail

Anticoagulation management in patients with atrial fibrillation undergoing elective electrical cardioversion

Speaker: Doctor O. Erkuner (Maastricht, NL)

Thumbnail

Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation

Speakers: Professor G. Lip, Doctor E. Ueno, Ms G. Stynes, Ms G. Stynes, Doctor M. Rohla...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk